Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumours. A randomised, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy after surgical resection of a primary gastrointestinal stromal tumour.
Related Articles
Senza categoria
When is it OK to randomise cancer patients to placebo?
Grandround
Managing adult soft tissue sarcomas and gastrointestinal stromal tumours
Senza categoria
Leave a Reply